UK +44 (0)1865 849841
Malaysia +60 3 2117 5193

Tag: liquid biopsy

How to translate biomarker discoveries into clinical applications

Extracellular vesicles provide an exciting opportunity as a modality for non-invasive biomarkers, which may enable them to be used as biomarkers for tumour metastasis.  

Read More

ctDNA and AI are the way forward in early cancer detection and metastatic treatment

We spoke with Dr David Guttery about his pioneering work using circulating tumour DNA to enable early detection, monitoring and therapeutic decision making for better patient outcomes in gynaecological cancers.

Read More

Strategic screening enables effective biomarker discovery

During my eight years at the Max Planck Institute for Molecular Genetics in Berlin, I led a protein technologies group. We developed a protein expression library, and then high-content protein arrays. In total, we made arrays with 10,000 different human proteins.

Read More

Why do biomarkers fail?

When conducting an experiment to identify biomarkers, it is crucial to design the experiment properly. 80-90% of all biomarker populations for the last 20 years have not and cannot be reproduced, and the main reason that biomarkers fail is that these experiments are not designed properly. In this post, I will outline two ways in which experiments are poorly designed, and then outline the technological and methodological solution in a later blog.

Read More

Identifying biomarkers to track tumour burden in patient blood

There is a huge need to identify biomarkers to discern which metastatic colorectal cancer patients will benefit from treatment using Regorafenib. Despite being the latest approved drugs for the disease, Regorafenib has limited clinical efficacy and is associated with a number of side effects. However, a lot of patients are treated with Regorafenib as it is the only treatment available for patients who cannot receive anti-EGFR treatment due to K-RAS or BRAF mutation.

Read More

The Development and Commercialisation of Robust Circulating DNA & RNA Tests

Precision medicine in oncology requires matching each patient with treatment personalised to their genes and often the proteomic profile of their cancer. Liquid biopsies continue to gain grounds as a tool for diagnostic testing in oncology.

Read More

Highlights From The 4th Global Precision Medicine & Biomarkers Leaders Summit

With just 3 months to go until the Precision Medicine & Biomarkers Leaders Summit: USA, we have taken some time to reflect on the Euopean Precision Medicine & Biomarkers Leaders Summit that took place in Munich in September. 

Read More

Honey Reddi on Liquid Biopsies and her Predictions for Precision Medicine

Honey Reddi, Clinical Laboratory Director at the Jackson Laboratory spoke at the 4th Global Precision Medicine and Biomarkers Leader Summit. She gives us an insight on liquid biopsies in the clinic and the effectiveness of current treatment.

Read More

Subscribe to Our Newsletter

Get free reports and resources from our world class speakers.
  • This field is for validation purposes and should be left unchanged.

Life Sciences Twitter Feed

Archive